Pump, Infusion, Insulin(LZG)

インスリン輸液ポンプ この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。

米国回収

126 件

直近 2026.07.08

510(k)

85 件

PMA

0 件

不具合報告

539,953 件

分類情報

Product Code LZG
デバイス名 Pump, Infusion, Insulin

インスリン輸液ポンプ この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。

デバイスクラス クラス II
21 CFR 規制番号 880.5725
審査区分 510(k)(市販前届出)
医療専門分野 一般病院用
定義 -
フラグ
該当なし
AI分析

本機器は米国では一般医療機器規制上のクラスIIに分類されており、市販前届出(510(k))による審査を通じて安全性・有効性が確認される区分に位置づけられています。クラスIIは中等度のリスクを有する医療機器を対象とし、既存の同等品との実質的同等性を示すことで市販が認められる制度です。

米国市場での動向

510(k)による市販前届出は累計約80件、参入企業数は29社で、直近5年間では約5件の届出があり、最新の判定は2026年4月となっています。不具合報告(MDR)は累計約53万8,000件と多く、その内訳は不具合(Malfunction)が約43万9,000件と大半を占める一方、死亡報告は1,409件、傷害報告は約96,000件となっており、主な問題としてUnintended Movement(意図しない動作)、Loss of or Failure to Bond(接合不良・接合失敗)、Material Twisted/Bent(部材のねじれ・変形)が挙げられています。回収は累計約130件で、クラスI(最重篤)が11件、クラスIIが28件、クラスIIIが2件含まれており、直近5年間では約5件、最新の回収は2026年5月に開始されています。

この分析は公開データ(openFDA・JMDN 対応情報)をもとに AI が生成した参考情報です。市場データは2026年8月時点の集計に基づきます。

関連 product code

同じ 21 CFR 880.5725 に分類される product code(16 件)

No.product code機器名クラス専門分野510(k)PMA不具合回収
1FRN

Pump, Infusion

輸液ポンプ

II一般病院用849—1,831,043718 件
2MEB

Pump, Infusion, Elastomeric

エラストマー式輸液ポンプ

II一般病院用88—33,515109 件
3LGZ

Warmer, Thermal, Infusion Fluid

輸液加温装置

II一般病院用75—7,00232 件
4LDR

Controller, Infusion, Intravascular, Electronic

電子式血管内輸液コントローラ

II一般病院用60—735 件
5MRZ

Accessories, Pump, Infusion

輸液ポンプ用アクセサリ

II一般病院用48—5408 件
6LZH

Pump, Infusion, Enteral

経腸栄養用輸液ポンプ

II一般病院用34—14,92224 件
7MEA

Pump, Infusion, Pca

PCA用輸液ポンプ

II一般病院用31—32,85846 件
8MRH

Pump, Infusion, Ophthalmic

眼科用輸液ポンプ

II一般病院用20—138—
9PHC

Infusion Safety Management Software

輸液安全管理ソフトウェア

II一般病院用10—8813 件
10LZF

Pump, Infusion, Analytical Sampling

分析サンプリング輸液ポンプ

II一般病院用7—21 件
11OPP

Pump, Infusion, Insulin Bolus

インスリンボーラス注入ポンプ

II一般病院用7—361 件
12PKP

Immunoglobulin G (Igg) Infusion System

免疫グロブリンG注入システム

II一般病院用7—7—

機器名の日本語訳は AI により自動生成したものです。正確には英語原文をご確認ください。

類似の国内医療機器(自動推定)

FDA デバイス分類と JMDN 英語名の名称・定義文の類似度から機械的に推定した候補です。日米の当局が定めた公的な対応関係ではなく、参考情報としてご覧ください。

No.類別一般的名称品目数企業数年間総出荷額成長率平均価格国産比率
1医薬品注入器ポータブルインスリン用輸液ポンプクラスⅢ9436.86 億円/年+104.7% 7,134 円/個72.3%
2医薬品注入器インスリンポンプ用輸液セットクラスⅡ5316.29 億円/年+336.3% 829 円/個6.4%
3内臓機能検査用器具インフュージョンポンプクラスⅡ11————
4医薬品注入器非静注インフュージョンポンプクラスⅡ32————
5医薬品注入器注射筒輸液ポンプクラスⅢ301129.72 億円/年-13.3% 17.82 万円/個98.8%

FDA のデバイスクラスは 3 段階(クラス I〜III)、日本の医療機器は 4 段階(クラス I〜IV)で分類されており、 1 対 1 では対応しません。 リスク区分の考え方が異なるため、参考情報としてご利用ください。

米国での回収・承認・不具合報告

無料会員 1,000名 突破

回収・承認・不具合報告の明細の閲覧は会員限定です

無料で会員登録する
回収番号クラス回収開始日企業理由ステータス
Z-2605-2026 LZGクラス I(最重篤)2026.05.20Insulet Corporation

External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.

対応中
Z-2604-2026 LZGクラス I(最重篤)2026.05.20Insulet Corporation

External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.

対応中
Z-1748-2026 LZGクラス II2026.02.13Medtronic MiniMed, Inc.

All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.

対応中
Z-1255-2025 LZGクラス II2025.01.31Medtronic MiniMed, Inc.

All Medtronic MiniMed pumps (Paradigm series, Minimed 530G, 6XX series, and 7XX series) were found to have the potential for abnormal insulin delivery due to changes in air pressure, which can be found during airplane take-off or landing. An unexpected additional dose of insulin, which can occur during take-off, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An unexpected under-delivery of insulin, which can occur during landing, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death. During a delivery accuracy dry run testing of the 780G NGP infusion pump under dynamic pressure conditions, the firm observed that when air pressure decreased during take-off simulation, on average 0.569U more insulin was delivered in 15 minutes than the expected delivery volume at ambient pressure at 1 U/hr delivery rate; when air pressure increased during landing simulation, on average 0.537 U less insulin was delivered in 25 minutes than the expected delivery volume at ambient pressure at 1 U/hr delivery rate. The firm also observed that the mechanisms causing the variations in delivery volumes are independent of the delivery rate.

対応中
Z-0154-2023 LZGクラス I(最重篤)2022.10.17Insulet Corporation

The firm has become aware of PDM battery issues, including battery swelling, fluid leaking from the battery, and extreme overheating, which may pose a fire hazard. The firm has received a complaint alleging fire as a result of thermal energy from a DASH PDM.

終了
Z-2351-2021 LZGクラス II2021.07.28Roche Diabetes Care, Inc.

Test strip vials may open while inside sealed cartons during shipment. An open vial might expose the test strips to humidity, which might damage the strips and result in inaccurate results, potentially leading to inappropriate therapy decisions and adverse health consequences.

対応中
Z-1203-2021 LZGクラス II2021.02.01Insulet Corporation

Certain foreign user guides include a misprint which could lead to an incorrect bolus delivery and hypoglycemia. Only Outside the US (OUS): Error in the Omnipod DASH User Guide text, page 6 of the User Guide, the text states that the comma (,) is not used for the decimal on the PDM, when in fact it is the period (.) that is not used.If a user were to use the period as a decimal separator when entering a bolus value, this decimal separator would not be recognized by the device and any numbers entered after the period could result in a larger value than intended

終了
Z-2165-2020 LZGクラス II2020.04.02Insulet Corporation

After the device has been in use for about 2 months, data processing in the PDM can be slowed such that the Bolus Calculator fails to accurately subtract the correct amout of IOB before suggesting a bolus amount.

終了
Z-2164-2020 LZGクラス II2020.04.02Insulet Corporation

After the device has been in use for about 2 months, data processing in the PDM can be slowed such that the Bolus Calculator fails to accurately subtract the correct amout of IOB before suggesting a bolus amount.

終了
Z-1553-2020 LZGクラス II2020.02.13Insulet Corporation

In certain scenarios, the Omnipod DASH PDM may suggest an inaccurate bolus amount based on a blood glucose value that is more than 10 minutes old when the user does not exit the bolus calculator as designed or when a system alarm interrupts a bolus calculation. If the user delivers the bolus, this may lead to hypoglycemia or hyperglycemia.

終了
Z-0199-2020 LZGクラス II2019.07.03Valeritas, Incorporated

There is a potential for "No Needle Demo Units" to contain a needle.

終了
Z-0198-2020 LZGクラス II2019.07.03Valeritas, Incorporated

There is a potential for "No Needle Demo Units" to contain a needle.

終了
Z-0197-2020 LZGクラス II2019.07.03Valeritas, Incorporated

There is a potential for "No Needle Demo Units" to contain a needle.

終了
Z-0196-2020 LZGクラス II2019.07.03Valeritas, Incorporated

There is a potential for "No Needle Demo Units" to contain a needle.

終了
Z-0195-2020 LZGクラス II2019.07.03Valeritas, Incorporated

There is a potential for "No Needle Demo Units" to contain a needle.

終了
Z-1586-2020 LZGクラス II2019.06.27Medtronic MiniMed

The action is being initiated due to potential cybersecurity vulnerabilities related to a series of insulin pumps that are designed to communicate using a wireless radio frequency (RF). An unauthorized person could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery.

対応中
Z-1585-2020 LZGクラス II2019.06.27Medtronic MiniMed

The action is being initiated due to potential cybersecurity vulnerabilities related to a series of insulin pumps that are designed to communicate using a wireless radio frequency (RF). An unauthorized person could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery.

対応中
Z-1584-2020 LZGクラス II2019.06.27Medtronic MiniMed

The action is being initiated due to potential cybersecurity vulnerabilities related to a series of insulin pumps that are designed to communicate using a wireless radio frequency (RF). An unauthorized person could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery.

対応中
Z-1583-2020 LZGクラス II2019.06.27Medtronic MiniMed

The action is being initiated due to potential cybersecurity vulnerabilities related to a series of insulin pumps that are designed to communicate using a wireless radio frequency (RF). An unauthorized person could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery.

対応中
Z-1582-2020 LZGクラス II2019.06.27Medtronic MiniMed

The action is being initiated due to potential cybersecurity vulnerabilities related to a series of insulin pumps that are designed to communicate using a wireless radio frequency (RF). An unauthorized person could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery.

対応中

510(k)(市販前届出)

全 85 件
No.番号機器名申請者決定日種別概要
1K262153 Pivot Insulin Delivery SystemModular Medical, Inc.2026.09.02通常(Traditional) PDF
2K253534 Pivot Insulin Delivery SystemModular Medical2026.04.08通常(Traditional) PDF
3K240158 Modular Medical MODD1 Insulin Delivery SystemModular Medical, Inc.2024.09.04通常(Traditional) PDF
4K241622 Extended Reservoir; MiniMed ReservoirMedtronic Minimed2024.07.02特別(Special) PDF
5K223372 Omnipod GO Insulin Delivery DeviceInsulet Corporation2023.04.24通常(Traditional) PDF
6K210714 Extended ReservoirMedtronic Minimed, Inc.2022.04.06通常(Traditional) PDF
7K211575 Omnipod® Insulin Management System, Omnipod DASH® Insulin Management SystemInsulet Corporation2021.08.13通常(Traditional) PDF
8K192659 Omnipod Insulin Management System, Omnipod DASH Insulin Management SystemInsulet Corporation2019.10.21通常(Traditional) PDF
9K182630 Omnipod Insulin Management System, Omnipod DASH Insulin Management SystemInsulet Corporation2019.01.08通常(Traditional) PDF
10K180045 Omnipod DASH Insulin Management SystemInsulet Corporation2018.06.01通常(Traditional) PDF
11K162296 OmniPod Insulin Management SystemInsulet Corporation2017.04.18通常(Traditional) PDF
12K162080 t:slim Insulin Delivery System, t:flex Insulin Delivery System, Tandem Device UpdaterTandem Diabetes Care, Inc.2016.10.25通常(Traditional) PDF
13K160056 t:slim Insulin Delivery SystemTandem Diabetes Care, Inc.2016.07.25通常(Traditional) PDF
14K160482 t:slim Insulin Delivery System, t:flex Insulin Delivery System, Tandem Device UpdaterTandem Diabetes Care, Inc.2016.07.13通常(Traditional) PDF
15K160252 OmniPod Insulin Management SystemInsulet Corporation2016.04.27通常(Traditional) PDF
16K143189 t:flex Insulin Delivery SystemTandem Diabetes Care, Inc.2015.01.09通常(Traditional) PDF
17K142619 Snap Insulin Pump SystemAsante Solutions, Inc.2014.12.18特別(Special) PDF
18K140439 OMNIPOD INSULIN MANAGEMENT SYSTEMInsulet Corporation2014.11.13通常(Traditional) PDF
19K141758 T:SLIM INSULIN DELIVERY SYSTEMTandem Diabetes Care, Inc.2014.10.31通常(Traditional) PDF
20K133593 T:SLIM INSULIN DELIVERY SYSTEMTandem Diabetes Care, Inc.2014.03.24特別(Special) PDF

出典の openFDA は各 510(k) の主要(primary)product code のみを収録しているため、副次コードを含む FDA 公式データベースの検索結果とは件数が異なる場合があります。 FDA 510(k) データベースで確認

PMA(市販前承認)

この product code の PMA 情報はありません。

不具合報告(MAUDE)トレンド

米国不具合報告検索で詳しく見る

出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。

報告の存在は、機器と事象の因果関係を意味しません。報告件数を機器間の不具合発生率の比較に用いることはできません。

各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。

不具合報告データを読み込み中...

出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。

取得日: 2026.09.28

各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。